[Phosphate binder up to date]

Area of Science:

• Nephrology
• Internal Medicine
• Clinical Pharmacology

Background:

• Hyperphosphatemia is a major risk factor for survival in patients undergoing renal replacement therapy.
• Ectopic calcification, such as vascular calcification, is a key mechanism linking hyperphosphatemia to reduced survival.
• While renal replacement therapy removes phosphate, it is often insufficient, necessitating the use of phosphate binders to reduce intestinal absorption.

Purpose of the Study:

• To review the role of phosphate binders in managing hyperphosphatemia in patients on renal replacement therapy.
• To discuss the limitations and adverse effects of existing phosphate binders.
• To evaluate the potential of novel phosphate binders, specifically lanthanum carbonate.

Main Methods:

• Literature review of studies on hyperphosphatemia management in renal replacement therapy.
• Analysis of the efficacy and safety profiles of common phosphate binders (calcium carbonate, sevelamer hydrochloride).
• Examination of emerging phosphate binders, focusing on lanthanum carbonate.

Main Results:

• Aluminum compounds have been prohibited due to severe adverse effects.
• Combination therapy with calcium carbonate and sevelamer hydrochloride is often recommended to mitigate individual drug toxicities.
• Lanthanum carbonate is a developing non-calcium, non-aluminum phosphate binder with a potent phosphate-binding capacity, though its adverse effects remain under investigation.

Conclusions:

• Effective management of hyperphosphatemia is critical for improving survival in patients on renal replacement therapy.
• Current phosphate binders have limitations and potential adverse effects, necessitating combination therapies or novel agents.
• Lanthanum carbonate represents a promising new option, but further research is required to fully elucidate its safety profile.